CD95/Fas stoichiometry in future precision medicine

被引:0
|
作者
Sica, Mauricio [1 ]
Roussel, Murielle [2 ,3 ]
Legembre, Patrick [2 ]
机构
[1] Inst Balseiro UNCuyo, Bariloche Atom Ctr, CONICET, Dept Fis Med GAANS CNEA, Ave Bustillo 9500, San Carlos De Bariloche, Rio Negro, Argentina
[2] Univ Limoges, UMR CNRS 7276, INSERM U1262, CRIBL, 2 Rue Marcland, Limoges, France
[3] CHU Dupuytren, Clin Hematol & Cellular Therapy Dept, Limoges, France
关键词
OSTEOCLAST DIFFERENTIATION FACTOR; FAS LIGAND; SIGNALING PATHWAY; DECOY RECEPTOR; DEATH DOMAIN; TNF; COMPLEX; CELLS; OSTEOPROTEGERIN; IDENTIFICATION;
D O I
10.1038/s41418-025-01493-9
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
CD95, also known as Fas, belongs to the tumor necrosis factor (TNF) receptor superfamily. The main biological function of this receptor is to orchestrate and control the immune response since mutations in CD95 or deregulation of its downstream signaling pathways lead to auto-immunity and inflammation. Interestingly, more than twenty years ago, pioneer studies highlighted that like TNFR1, TRAILR1 or CD40, CD95 pre-associates at the plasma membrane in a ligand-independent fashion. This self-association occurs through a domain designated pre-ligand assembly domain or PLAD. Although the disruption of this pre-association prevents CD95 signaling, no drugs targeting this region have been generated because many questions remain on the stoichiometry and conformation of this receptor. Despite more than 40.000 publications, no crystal structure of CD95 alone or in combination with its ligand, CD95L, exists. Based on other TNFR members, we herein discuss the predicted conformation of CD95 at the plasma membrane and how these putative structures might account for the induction of the cell signaling pathways.
引用
收藏
页数:8
相关论文
共 50 条
  • [21] Analysis of apoptotic markers Fas/FasL (CD95/CD95L) expression on the lymphocytes in patients with acute coronary syndrome
    Bossowska, Anna
    Bossowski, Artur
    Galar, Bogdan
    KARDIOLOGIA POLSKA, 2007, 65 (08) : 883 - 892
  • [22] Fas (Apo-1/CD95) and Fas ligand interaction between gastric cancer cells and immune cells
    Lee, TB
    Min, YD
    Lim, SC
    Kim, KJ
    Jeon, HJ
    Choi, SM
    Choi, CH
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2002, 17 (01) : 32 - 38
  • [23] Fas/CD95 prevents autoimmunity independently of lipid raft localization and efficient apoptosis induction
    Cruz, Anthony C.
    Ramaswamy, Madhu
    Ouyang, Claudia
    Klebanoff, Christopher A.
    Sengupta, Prabuddha
    Yamamoto, Tori N.
    Meylan, Francoise
    Thomas, Stacy K.
    Richoz, Nathan
    Eil, Robert
    Price, Susan
    Casellas, Rafael
    Rao, V. Koneti
    Lippincott-Schwartz, Jennifer
    Restifo, Nicholas P.
    Siegel, Richard M.
    NATURE COMMUNICATIONS, 2016, 7
  • [24] Raft component GD3 associates with tubulin following CD95/Fas ligation
    Sorice, Maurizio
    Matarrese, Paola
    Tinari, Antonella
    Giammarioli, Anna Maria
    Garofalo, Tina
    Manganelli, Valeria
    Ciarlo, Laura
    Gambardella, Lucrezia
    Maccari, Giorgio
    Botta, Maurizio
    Misasi, Roberta
    Malorni, Walter
    FASEB JOURNAL, 2009, 23 (10) : 3298 - 3308
  • [25] Differential regulation of CD95 (Fas/APO-1) expression in human blood eosinophils
    Luttmann, W
    Opfer, A
    Dauer, E
    Foerster, M
    Matthys, H
    Eibel, H
    Schulze-Osthoff, K
    Kroegel, C
    Virchow, JC
    EUROPEAN JOURNAL OF IMMUNOLOGY, 1998, 28 (07) : 2057 - 2065
  • [26] Involvement of mitochondria and recruitment of Fas/CD95 signaling in lipid rafts in resveratrol-mediated antimyeloma and antileukemia actions
    Reis-Sobreiro, M.
    Gajate, C.
    Mollinedo, F.
    ONCOGENE, 2009, 28 (36) : 3221 - 3234
  • [27] CD95/Fas ligand mRNA is toxic to cells through more than one mechanism
    Haluck-Kangas, Ashley
    Fink, Madelaine
    Bartom, Elizabeth T.
    Peter, Marcus E.
    MOLECULAR BIOMEDICINE, 2023, 4 (01):
  • [28] Prognostic impact of FAS/CD95/APO-1 in urothelial cancers: decreased expression of Fas is associated with disease progression
    K Yamana
    V Bilim
    N Hara
    T Kasahara
    T Itoi
    R Maruyama
    T Nishiyama
    K Takahashi
    Y Tomita
    British Journal of Cancer, 2005, 93 : 544 - 551
  • [29] CD95 gene deletion may reduce clonogenic growth and invasiveness of human glioblastoma cells in a CD95 ligand-independent manner
    Quijano-Rubio, Clara
    Silginer, Manuela
    Weller, Michael
    CELL DEATH DISCOVERY, 2022, 8 (01)
  • [30] Prognostic impact of FAS/CD95/APO-1 in urothelial cancers: decreased expression of Fas is associated with disease progression
    Yamana, K
    Bilim, V
    Hara, N
    Kasahara, T
    Itoi, T
    Maruyama, R
    Nishiyama, T
    Takahashi, K
    Tomita, Y
    BRITISH JOURNAL OF CANCER, 2005, 93 (05) : 544 - 551